Digital Health Benchmarking, Clinical Confirmation and Lifecyle Validation

Forecast New Requirement Updated

Agency
Solicitation expected
Estimated value
$1,500,000 to $3,000,000
Set-aside
No set-aside

Forecast facts

Anticipated award
NAICS code
Not on record
Points of contact

Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.

About this forecast

The Food and Drug Administration is procuring services to build end-to-end capability for digital health medical device evaluation across premarket review, evaluation science, and postmarket oversight, with solicitation estimated for release on February 1, 2027, and award targeted for August 1, 2027. The program will develop clinically grounded failure-mode taxonomies, benchmark design principles, evaluation protocols, reusable test sets or specifications where feasible, methods for weighting clinically consequential errors, approaches for subgroup and use-context analysis, and frameworks for assessing digital health confirmation and post-update performance.

The estimated award value ranges from $1.5 million to $3 million. Inquiries should be directed to the FDA's Center for Devices and Radiological Health Acquisitions mailbox at cdhracquisitions@fda.hhs.gov.

Forecast text

build FDA's end-to-end capability for new and innovative digital health medical devices across (1) premarket review, (2) evaluation science, and (3) postmarket oversight. The program would develop clinically grounded failure-mode taxonomies, benchmark design principles, evaluation protocols, reusable test sets or specifications where feasible, methods for weighting clinically consequential errors, approaches for subgroup and use-context analysis, and frameworks for assessing digital health confirmation and post-update performance

On GovTribe

Work this forecast

  • Track it in your pipeline
  • Find teaming partners
  • Similar forecasts
  • Ask GovTribe AI about this forecast